SynthesisCardiovascular drugs and therapy2026
Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants in the Extended Treatment of Venous Thromboembolism: A Systematic Review and Meta-Analysis.
Synthesis in Cardiovascular drugs and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Reduced-Dose Versus Full-Dose Direct Oral Anticoagulants for Extended Treatment of Venous Thromboembolism.Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/HemostasisPooled it
- Management of patients with protein s deficiency: focus on clinical course and direct oral anticoagulants.Thrombosis journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThe optimal dosing strategy for direct oral anticoagulants (DOACs) in extended treatment of venous thromboembolism (VTE) remains debated, particularly in balancing efficacy and bleeding risk.
methodsA systematic review and meta-analysis was performed to compare reduced-dose versus full-dose DOACs for extended VTE treatment. Databases including PubMed, Embase, and Cochrane Library were searched from inception to March 2025 for randomized controlled trials (RCTs) involving adult patients treated with different DOAC doses for VTE. Primary outcomes were recurrent VTE, major or clinically relevant non-major bleeding, and all-cause mortality. Subgroup analysis was conducted by DOAC type (apixaban vs. rivaroxaban).
resultsPooled data from 4 studies involving 8421 patients showed no statistically significant difference in recurrent VTE risk between reduced-dose and full-dose DOACs (RR = 0.94; 95% CI, 0.64-1.37; p = 0.75). Bleeding events were significantly lower in the reduced-dose group compared to the full-dose group (RR = 0.71; 95% CI, 0.61-0.82, p < 0.00001). All-cause mortality did not differ significantly between groups (RR = 0.80; 95% CI, 0.54-1.18; p = 0.25). Subgroup analysis showed consistent findings across DOAC type, with no significant interaction effects.
conclusionReduced-dose DOACs appear to be as effective as full-dose DOACs in preventing VTE, with a favorable safety profile due to reduced bleeding risk. These findings support reduced-dose DOACs as a viable option for extended anticoagulation in VTE patients.
Indexed as
Identifiers
40844745What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.